As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Nasus Pharma Ltd. The largest reported stake is Udi Gilboa's, at 21.1%. 7 filings are on record since August 20, 2025 (Schedule 13G, November 10, 2025).
Sell to companies like Nasus Pharma Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Balyasny Asset Management L.P. · Sole voting: 1,169,909 · Shared voting: 0 · Sole dispositive: 1,169,909 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Balyasny Asset Management L.P. · Percent: 9.99% · SCHEDULE 13G
- · Holder: Funicular Funds, LP · Percent: 5.2% · SCHEDULE 13G
- · Holder: Dr. Ronnie Hershman · Percent: 15.3% · SCHEDULE 13G
- · Holder: Dr. Dalia Megiddo · Percent: 20.9% · SCHEDULE 13G
Nasus Pharma Ltd. has 7 Schedule 13D or 13G filings on record since 2025-08-20. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 21.1% | 1,901,311 | SCHEDULE 13G, 2025-11-10 | 2025-09-30 | |
| 20.9% | 1,888,873 | SCHEDULE 13G, 2025-11-12 | 2025-09-30 | |
| 15.3% | 1,383,512 | SCHEDULE 13G, 2025-11-13 | 2025-09-30 | |
| Balyasny Asset Management L.P. | 9.99% | 1,169,909 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Capital Point Ltd. | 6.35% | 575,129 | SCHEDULE 13G, 2025-08-20 | 2025-08-14 |
| Funicular Funds, LP | 5.2% | 612,913 | SCHEDULE 13G, 2026-04-07 | 2026-03-31 |
Holding shares or following this stake? See who's behind Nasus Pharma Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Nasus Pharma Ltd. and the records around it.
Nasus Pharma Ltd. elsewhere on the record
- IPO filing Mar 2026
- Form D filing Feb 2026
- Who owns it
Companies that share a holder
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
- Balyasny Asset Management L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
Watch Nasus Pharma Ltd.
Get an email when Nasus Pharma Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nasus Pharma Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Nasus Pharma Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nasus Pharma Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Balyasny Asset Management L.P. | 1,169,909 | 0 | 1,169,909 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Bam Gp LLC | 1,169,909 | 0 | 1,169,909 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Balyasny Asset Management Holdings LP | 1,169,909 | 0 | 1,169,909 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dames GP LLC | 1,169,909 | 0 | 1,169,909 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dmitry Balyasny | 1,169,909 | 0 | 1,169,909 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Nasus Pharma Ltd. by CUSIP M7071P109 and gives its principal executive office as 29 Harakevet Street, Tel Aviv (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.99% of the Shares, based on 11,710,808 Shares outstanding as of March 27, 2026, as reported in the Issuer's post-effective amendment to its registration statement on form F-1 filed with the Securities and Exchange Commission on March 27, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-20 | Capital Point Ltd. | 6.35% | SCHEDULE 13G |
| 2025-11-10 | Udi Gilboa | 21.1% | SCHEDULE 13G |
| 2025-11-12 | Dr. Dalia Megiddo | 20.9% | SCHEDULE 13G |
| 2025-11-13 | Dr. Ronnie Hershman | 15.3% | SCHEDULE 13G |
| 2026-04-07 | Funicular Funds, LP | 5.2% | SCHEDULE 13G |
| 2026-05-15 | Balyasny Asset Management L.P. | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Balyasny Asset Management L.P. | 9.99% | SCHEDULE 13G/A |
Questions about who owns Nasus Pharma Ltd.
Who owns Nasus Pharma Ltd.?
On this page, 6 holders' latest ownership filings report 5% or more of Nasus Pharma Ltd.: Udi Gilboa (21.1%, Schedule 13G, filed 2025-11-10), Dr. Dalia Megiddo (20.9%, Schedule 13G, filed 2025-11-12), Dr. Ronnie Hershman (15.3%, Schedule 13G, filed 2025-11-13), Balyasny Asset Management L.P. (9.99%, Schedule 13G/A, filed 2026-08-14) and Capital Point Ltd. (6.35%, Schedule 13G, filed 2025-08-20); 1 more is listed above.
Who are the largest shareholders of Nasus Pharma Ltd.?
By the share each holder's latest filing reports, the largest holders of Nasus Pharma Ltd. on this page are Udi Gilboa (21.1%), Dr. Dalia Megiddo (20.9%) and Dr. Ronnie Hershman (15.3%).
When did Udi Gilboa buy into Nasus Pharma Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Udi Gilboa on this page is the Schedule 13G, filed 2025-11-10, reporting 21.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Nasus Pharma Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 2, 2026 | IPO filing, Form F-1 | — | IPO filings | Source |
| February 25, 2026 | Form D, private offering | $15M sold | Form D page | Source |
| August 14, 2025 | IPO filing, Form 424B4 | $8 a share | IPO filings | Source |
| August 7, 2025 | IPO filing, Form F-1/A | — | IPO filings | Source |
| July 28, 2025 | IPO filing, Form F-1/A | — | IPO filings | Source |
| July 9, 2025 | IPO filing, Form F-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Nasus Pharma Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.